AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03500237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
Study NCT01901939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: daily tailored low level pedaling exercise at bedside
Study NCT04688489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbloading and maltodextrin
Description: The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
Study NCT03007615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intimate Lubricant Gel
Study NCT03273257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.
Study NCT03273257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given analogue to riociguat with matching tablets.
Study NCT03273257 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary endarterectomy
Description: PEA will be performed at the end of medical treatment (Day 90)
Study NCT03273257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary endarterectomy
Description: PEA will be performed at the end of medical treatment (Day 90)
Study NCT04216992 — intervention group
Intervention type: DEVICE
Intervention: Cone beam computed tomography
Description: The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
Study NCT04723667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 13-week multimodal intervention
Description: The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
Study NCT04723667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5-week health education programme
Description: The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
Study NCT03252665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
Study NCT03252665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
Study NCT03252665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
Study NCT04706494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlphaWave® LTheanine
Description: 200 mg of AlphaWave® LTheanine
Study NCT04706494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study NCT03908840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI 302
Description: TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
Study NCT03055286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP232291
Description: For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion.
Study NCT01173380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy nuts
Description: Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
Study NCT01173380 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Matched food
Description: Control food (matched for calories and macronutrients) per day for 4 weeks
Study NCT00625313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMY Model YA-60BB IOL
Description: Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
Study NCT03107715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Champion
Description: iPad-based behavioral intervention facilitated by researcher
Study NCT03107715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Messaging
Description: iPad based behavioral intervention facilitated by researcher
Study NCT03305159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Patients will receive povidone iodine for the surgical preparation of the vagina.
Study NCT03305159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine Gluconate
Description: Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
Study NCT03079739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fractional flow reserve
Description: assessment with FFR in at least one coronary lesion
Study NCT00506558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral Surgical Decompression with Instrumented Fusion
Description: Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
Study NCT00506558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Decompression With or Without Fusion
Description: Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
Study NCT00470249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
Study NCT00470249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: 1500 mg/m2 on day 2 of every 2-week cycle
Study NCT03504839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Subcutaneous ICD with same day discharge
Description: Receiving a SICD and discharged the same day
Study NCT00985127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered daily for 21 days
Study NCT00985127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.
Study NCT03945929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed.
Study NCT02048059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Study NCT02494804 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
Study NCT02494804 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CIK
Description: The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
Study NCT02831686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Study NCT02831686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Study NCT02831686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02831478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Applied liberally to the skin (Formulation: RB# Z16-071)
Study NCT02831478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen Lotion (RB# T78-190B)
Description: Applied liberally to the skin
Study NCT04368117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Directed and prescribe physical therapy program for severely burned patients
Study NCT04368117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Directed and prescribe physical therapy program for severely burned patients
Study NCT01898884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP 20629
Study NCT01898884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01766076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBMC collected for immune activation assays using flowcytometry
Study NCT03393611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
Study NCT03393611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
Study NCT03393611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 (Day -2)
Study NCT03393611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Human T-Lymphocyte Globulin
Description: Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
Study NCT03393611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo-Cord Stem Cell Transplantation
Description: Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
Study NCT00822601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
Study NCT00822601 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Comparator
Description: sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
Study NCT01766076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PBMC collected for immune activation assays using flowcytometry
Study NCT02350023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical latanoprost 0.005%
Description: Local application of the drug on affected skin/scalp
Study NCT02350023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical betamethasone 0.05%
Description: Local application of the drug on affected skin/scalp
Study NCT00380874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150- 600 mg/day (double blind in divided doses)
Study NCT00380874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03164551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GERI+ incubator
Description: The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.
Study NCT03164551 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional incubator
Description: The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
Study NCT01987778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
Study NCT02462603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC-589
Description: PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
Study NCT01475799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Replacement of the Aortic Stenotic Valve
Description: Treatment for patients with Severe Aortic Stenosis.
Study NCT01435850 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: primary total hip arthroplasty
Description: All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
Study NCT01435850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary total hip arthroplasty
Description: All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
Study NCT03336736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise
Description: The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires.
Study NCT01308203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release niacin/laropiprant
Description: Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
Study NCT01308203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
Study NCT03084653 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Close-ended survey will be performed to the participants. The survey consisted of 18 questions (Appendix). The first six questions (#1-6) were related with respondent's demographical and educational data and experiences of surgical and laparoscopic practices. There were five questions to determine preferred technique for first entry (#7-11), three questions for complications (#12-14), and remaining four questions for safety maneuvers (#15-18).
Study NCT00818077 — intervention group
Intervention type: OTHER
Intervention: Continuous Glucose Monitoring of Carbohydrate Intake
Description: Subjects eat standard breakfast and lunch and keep food records.
Study NCT01512017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalline cellulose simple occlusive dressing
Description: A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
Study NCT01512017 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: External use
Study NCT03577080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ET+RT+ NMES
Description: Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
Study NCT03577080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ET+RT+ NMES
Description: Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
Study NCT03974867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5Mg Tab
Description: Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;
Study NCT03974867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg
Description: Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;
Study NCT02464007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rSIFN-co
Description: Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
Study NCT03350282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GAA-creatine
Study NCT03350282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine
Study NCT03961737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsies
Description: Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients.
Study NCT01164293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atopy patch test with food allergen
Description: Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
Study NCT03125967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Philips GoLite Blu HF3429/60
Description: Exposure to daily morning colored light in the 440-485 nm wavelength range
Study NCT03125967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Philips LivingColor Aura 70998/60/48
Description: Exposure to daily morning colored light in the 625-740 nm wavelength range
Study NCT02188147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Term Wearable Defibrillator
Description: Short-term Wearable Defibrillator (SWD 1000)
Study NCT00608101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
Study NCT00608101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
Study NCT00740636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
Study NCT00740636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.